Therapeutic | Pepinemab |
Target | SEMA4D |
Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS |
Light Chain | DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (August '23) | Phase-II |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Bristol-Myers Squibb%3BChildren%27s Oncology Group%3BEmory University%3BMerck KGaA%3BNational Cancer Institute %28USA%29%3BTeva Pharmaceutical Industries%3BUCLAs Jonsson Comprehensive Cancer Center%3BVaccinex |
Conditions Approved | na |
Conditions Active | Huntington%27s disease%3BNon-small cell lung cancer%3BOsteosarcoma%3BSolid tumours%3BColorectal cancer%3BHead and neck cancer%3BMalignant melanoma%3BPancreatic cancer |
Conditions Discontinued | Multiple sclerosis |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]